Thank you for your continued support of our business.
We have received a request from institutions for an explanation regarding the subsidiaryization of Governance Partners Asia Limited Investment Partnership, disclosed on June 27th. The following is a description.

GNI is considering becoming a bridge between Chinese investors and Japanese companies by investing Chinese investors' funds into Japanese companies, in order to expand revenue after F351.

Chinese investors → GNI → Japanese companies (including licenses)

On the other hand, for the development of the Japanese pharmaceutical industry, we are considering selling health care products such as pharmaceuticals and biomaterials held by investment companies to the Chinese market.

Japanese companies' products → GNI → Chinese market

This is to ensure smooth implementation in the future.
With the expansion of sales in the Chinese market, we will aim to increase the valuation of the investment companies, gain capital gains or group them.